You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
20 May 2021
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
4 May 2021
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
1 March 2021
CatalYm Announces Key Management and Board Changes
28 January 2021
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
10 November 2020
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients